Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC

Abstract Background The relationship between epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) resistance, including osimertinib, and programmed cell death‐ligand 1 (PD‐L1) expression status in EGFR‐mutated non‐small cell lung carcinoma (NSCLC) remains unclear. Patients and Metho...

Full description

Bibliographic Details
Main Authors: Yusuke Hamakawa, Yoko Agemi, Aya Shiba, Toshiki Ikeda, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yukiko Nakamura, Tsuneo Shimokawa, Yusuke Saigusa, Nobuaki Kobayashi, Hiroaki Okamoto, Takeshi Kaneko
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
EGFR mutations
EGFR‐TKI
non‐small cell lung carcinoma
osimertinib
programmed cell death‐ligand 1
Online Access:https://doi.org/10.1002/cam4.6405

Internet

https://doi.org/10.1002/cam4.6405

Similar Items